Preserving Data Quality in Phase I Studies During COVID-19: A CRO's Perspective from the ExL Clinical Quality Oversight Forum recorded on October 21, 2020.

Inhaled studies are often perceived as technically challenging, and varied regulations around the world add another level of complexity. Understanding the guidelines, study design requirements, study timing and test article suitability will demystify and clarify inhaled studies optimizing success.

Bird's eye view of the new automated kit production line, now open for EMEA investigator sites at our European Operations Center.

Recent increases in regulatory scrutiny and focus emphasize the importance of quality antibody reagents. The majority of biotherapeutic programs have several critical reagents that require generation, storage/management and periodic retesting.

Learn how Functional Service Provider (FSP) models can best support sponsor-directed processes in Decentralized Clinical Trials (DCT).

Your source for answers to the complex challenges of cell and gene therapy development. We recently sat down with Maryland Franklin, Vice President and Enterprise Head of Cell & Gene Therapy at Labcorp Drug Development, to discuss key considerations for developing cell or gene therapies in today's quickly expanding pipeline.